Aytu Biopharma Inc Financials

AYTU

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE June

This page shows Aytu Biopharma Inc (AYTU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 31/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Aytu Biopharma Inc has an operating margin of -11.8%, meaning the company retains $-12 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2.4% the prior year.

Growth

Aytu Biopharma Inc's revenue grew a modest 1.8% year-over-year to $66.4M. This slow but positive growth earns a score of 34/100.

Leverage

Aytu Biopharma Inc carries a low D/E ratio of 0.57, meaning only $0.57 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Aytu Biopharma Inc's current ratio of 1.26 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Aytu Biopharma Inc generated -$1.9M in operating cash flow, capex of $228K consumed most of it, leaving -$2.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

4/9

Aytu Biopharma Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.14x

For every $1 of reported earnings, Aytu Biopharma Inc generates $0.14 in operating cash flow (-$1.9M OCF vs -$13.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-2.1x

Aytu Biopharma Inc earns $-2.1 in operating income for every $1 of interest expense (-$7.8M vs $3.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$66.4M

YoY+1.8%

5Y CAGR+19.2%

10Y CAGR+73.9%

Aytu Biopharma Inc generated $66.4M in revenue in fiscal year 2025. This represents an increase of 1.8% from the prior year.

EBITDA

-$2.5M

YoY-136.7%

Aytu Biopharma Inc's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 136.7% from the prior year.

Free Cash Flow

-$2.2M

YoY-26.1%

Aytu Biopharma Inc generated -$2.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 26.1% from the prior year.

Net Income

-$13.6M

YoY+14.4%

Aytu Biopharma Inc reported -$13.6M in net income in fiscal year 2025. This represents an increase of 14.4% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

$31.0M

YoY+54.7%

5Y CAGR-8.4%

10Y CAGR+15.5%

Aytu Biopharma Inc held $31.0M in cash against $10.9M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+50.3%

Aytu Biopharma Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 50.3% from the prior year.

Gross Margin

69.0%

YoY-6.2pp

5Y CAGR-1.0pp

10Y CAGR+2.7pp

Aytu Biopharma Inc's gross margin was 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.2 percentage points from the prior year.

Operating Margin

-11.8%

YoY-9.3pp

5Y CAGR+64.7pp

10Y CAGR+2903.7pp

Aytu Biopharma Inc's operating margin was -11.8% in fiscal year 2025, reflecting core business profitability. This is down 9.3 percentage points from the prior year.

Net Margin

-20.4%

YoY+3.9pp

5Y CAGR+28.9pp

10Y CAGR+2929.9pp

Aytu Biopharma Inc's net profit margin was -20.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.9 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$1.3M

YoY-52.1%

5Y CAGR-5.1%

10Y CAGR-8.5%

Aytu Biopharma Inc invested $1.3M in research and development in fiscal year 2025. This represents a decrease of 52.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$228K

YoY-30.7%

Aytu Biopharma Inc invested $228K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 30.7% from the prior year.

AYTU Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$66.4M+1.8%	$65.2M-39.3%	$107.4M+11.1%	$96.7M+47.3%	$65.6M+137.5%	$27.6M
Cost of Revenue	$20.6M+27.4%	$16.1M-60.4%	$40.8M-8.2%	$44.4M+21.8%	$36.4M+339.9%	$8.3M
Gross Profit	$45.8M-6.6%	$49.1M-26.4%	$66.6M+27.4%	$52.3M+79.1%	$29.2M+50.9%	$19.4M
R&D Expenses	$1.3M-52.1%	$2.8M-32.4%	$4.1M-67.7%	$12.7M+125.2%	$5.6M+226.5%	$1.7M
SG&A Expenses	$17.4M-12.9%	$20.0M-30.3%	$28.6M-8.1%	$31.2M+22.2%	$25.5M-26.7%	$34.8M
Operating Income	-$7.8M-392.0%	-$1.6M+90.7%	-$17.1M+84.5%	-$109.9M-86.7%	-$58.9M-178.6%	-$21.1M
Interest Expense	$3.7M-26.8%	$5.1M+1.9%	$5.0M+451.4%	$900K	N/A	$2.6M
Income Tax	$437K-79.6%	$2.1M	$0+100.0%	-$110K-142.5%	$259K	$0
Net Income	-$13.6M+14.4%	-$15.8M+7.1%	-$17.1M+84.3%	-$108.8M-86.6%	-$58.3M-327.9%	-$13.6M
EPS (Diluted)	N/A	N/A	$-5.11+93.1%	$-74.01	$-3.48	N/A

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Revenue	$15.2M+9.2%	$13.9M-24.7%	$18.5M+13.8%	$16.2M-2.1%	$16.6M+18.2%	$14.0M-25.2%	$18.7M+5.2%	$17.8M
Cost of Revenue	$5.5M+17.8%	$4.7M-16.7%	$5.6M+3.9%	$5.4M+18.4%	$4.6M+25.2%	$3.7M-11.6%	$4.1M-13.3%	$4.8M
Gross Profit	$9.6M+4.8%	$9.2M-28.3%	$12.8M+18.7%	$10.8M-10.0%	$12.0M+15.7%	$10.4M-29.0%	$14.6M+12.0%	$13.0M
R&D Expenses	$0	$0-100.0%	$162K-69.0%	$522K+22.5%	$426K-30.3%	$611K+17.3%	$521K-12.4%	$595K
SG&A Expenses	$5.1M+3.0%	$4.9M+19.8%	$4.1M-7.6%	$4.4M-13.2%	$5.1M+6.1%	$4.8M+0.6%	$4.8M-23.7%	$6.3M
Operating Income	-$2.0M-31.0%	-$1.5M-162.1%	$2.4M+242.8%	-$1.7M-82.3%	-$930K+41.8%	-$1.6M-150.8%	$3.1M+462.9%	-$867K
Interest Expense	$560K+8.5%	$516K-42.7%	$900K-16.6%	$1.1M+8.6%	$994K-20.9%	$1.3M-0.7%	$1.3M-1.3%	$1.3M
Income Tax	$0	$0+100.0%	-$122K+56.9%	-$283K-169.9%	$405K-22.3%	$521K-33.2%	$780K	$0
Net Income	-$10.6M-638.6%	$2.0M-50.8%	$4.0M+406.9%	$788K-46.5%	$1.5M+151.1%	-$2.9M-1212.3%	-$220K+97.3%	-$8.1M
EPS (Diluted)	$-1.05-1212.5%	$-0.08-138.1%	$0.21+180.8%	$-0.26-73.3%	$-0.15+71.2%	$-0.52-1200.0%	$-0.04+97.3%	$-1.48

AYTU Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$124.2M+5.2%	$118.1M-13.5%	$136.5M-0.8%	$137.6M-48.2%	$265.7M+73.3%	$153.3M
Current Assets	$79.2M+27.9%	$61.9M-15.0%	$72.8M+21.5%	$59.9M-43.1%	$105.2M+39.5%	$75.4M
Cash & Equivalents	$31.0M+54.7%	$20.0M-13.0%	$23.0M+18.7%	$19.4M-61.0%	$49.6M+3.3%	$48.1M
Inventory	$11.4M-5.8%	$12.1M+1.2%	$12.0M+10.6%	$10.8M-33.6%	$16.3M+63.4%	$10.0M
Accounts Receivable	$31.2M+32.4%	$23.5M-18.7%	$28.9M+33.3%	$21.7M-22.9%	$28.2M+400.2%	$5.6M
Goodwill	N/A	N/A	$0	$0-100.0%	$65.8M+134.3%	$28.1M
Total Liabilities	$105.2M+16.4%	$90.4M-6.9%	$97.1M+4.1%	$93.3M-27.2%	$128.1M+119.8%	$58.3M
Current Liabilities	$63.1M+1.3%	$62.2M-9.8%	$69.0M+7.1%	$64.4M-41.1%	$109.4M+280.5%	$28.8M
Long-Term Debt	$10.9M+0.2%	$10.9M-26.1%	$14.7M-1.9%	$15.0M+8233.3%	$180K	$0
Total Equity	$19.0M-31.6%	$27.7M-29.6%	$39.4M-11.2%	$44.3M-67.8%	$137.6M+44.8%	$95.0M
Retained Earnings	-$333.5M-4.2%	-$320.0M-5.2%	-$304.1M-5.9%	-$287.1M-61.0%	-$178.3M-48.6%	-$120.0M

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Total Assets	$122.0M-2.4%	$125.0M+0.6%	$124.2M+6.9%	$116.2M+0.3%	$115.8M-10.1%	$128.9M-1.8%	$131.2M-1.2%	$132.9M
Current Assets	$76.2M-6.0%	$81.1M+11.9%	$72.5M+17.2%	$61.9M	N/A	$71.1M-0.3%	$71.4M+1.1%	$70.6M
Cash & Equivalents	$30.0M-8.0%	$32.6M+79.6%	$18.2M-10.9%	$20.4M+1.4%	$20.1M+1.8%	$19.8M+1.2%	$19.5M-2.2%	$20.0M
Inventory	$8.7M-14.3%	$10.1M-8.7%	$11.1M-0.2%	$11.1M-5.6%	$11.7M-11.0%	$13.2M+1.5%	$13.0M+0.3%	$13.0M
Accounts Receivable	$30.9M-6.9%	$33.2M-7.3%	$35.8M+41.0%	$25.4M+9.7%	$23.2M-22.6%	$29.9M+1.8%	$29.4M-1.6%	$29.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Total Liabilities	$107.8M+5.9%	$101.8M+14.0%	$89.3M+4.5%	$85.5M-0.6%	$86.0M-12.3%	$98.1M-0.3%	$98.4M-2.3%	$100.7M
Current Liabilities	$65.6M-0.7%	$66.0M-6.7%	$70.7M+10.4%	$64.0M+4.6%	$61.3M-26.8%	$83.7M+30.4%	$64.2M-1.9%	$65.5M
Long-Term Debt	$10.0M-4.3%	$10.4M+9.6%	$9.5M-4.5%	$10.0M-4.3%	$10.4M	$0-100.0%	$15.0M-0.1%	$15.0M
Total Equity	$14.2M-38.7%	$23.2M-33.6%	$34.9M+13.4%	$30.8M+3.1%	$29.8M-3.1%	$30.8M-6.3%	$32.9M+2.1%	$32.2M
Retained Earnings	-$342.2M-3.2%	-$331.6M-5.7%	-$313.7M+1.3%	-$317.7M+0.2%	-$318.5M-1.0%	-$315.4M-0.9%	-$312.5M-0.1%	-$312.2M

AYTU Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.9M-39.6%	-$1.4M+72.9%	-$5.1M+82.2%	-$28.8M-11.0%	-$26.0M+8.5%	-$28.4M
Capital Expenditures	$228K-30.7%	$329K	N/A	$0-100.0%	$2.3M	$0
Free Cash Flow	-$2.2M-26.1%	-$1.7M	N/A	-$28.8M-1.8%	-$28.3M+0.2%	-$28.4M
Investing Cash Flow	-$2.6M-678.1%	-$329K-181.2%	-$117K+96.4%	-$3.2M-16.8%	-$2.8M+50.8%	-$5.7M
Financing Cash Flow	$15.4M+1323.7%	-$1.3M-114.2%	$8.9M+479.8%	$1.5M-95.0%	$30.3M-57.3%	$71.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Operating Cash Flow	$3.7M+694.7%	-$618K+90.4%	-$6.5M-322.2%	$2.9M+344.1%	-$1.2M-368.5%	-$254K-88.1%	-$135K+36.0%	-$211K
Capital Expenditures	$17K	$0-100.0%	$69K+1050.0%	$6K-95.6%	$136K	$0	N/A	N/A
Free Cash Flow	$3.7M+691.9%	-$618K+90.5%	-$6.5M-325.0%	$2.9M+318.6%	-$1.3M-422.0%	-$254K	N/A	N/A
Investing Cash Flow	-$17K	$0+100.0%	-$69K-147.6%	$145K-61.9%	$381K+946.7%	-$45K+74.1%	-$174K-128.9%	-$76K
Financing Cash Flow	-$6.3M-372.8%	$2.3M-46.6%	$4.3M+255.8%	-$2.8M-403.0%	$911K+71.9%	$530K+520.6%	-$126K+95.4%	-$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AYTU Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	69.0%-6.2pp	75.3%+13.2pp	62.0%+8.0pp	54.1%+9.6pp	44.5%-25.5pp	70.0%
Operating Margin	-11.8%-9.3pp	-2.4%+13.5pp	-15.9%+97.8pp	-113.7%-24.0pp	-89.7%-13.2pp	-76.5%
Net Margin	-20.4%+3.9pp	-24.3%-8.4pp	-15.9%+96.6pp	-112.5%-23.7pp	-88.8%-39.5pp	-49.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-10.9%+2.5pp	-13.4%-0.9pp	-12.5%+66.5pp	-79.0%-57.1pp	-21.9%-13.1pp	-8.9%
Current Ratio	1.26+0.3	0.99-0.1	1.06+0.1	0.93-0.0	0.96-1.7	2.62
Debt-to-Equity	0.57+0.2	0.39+0.0	0.37+0.0	0.34+0.3	0.000.0	0.00
FCF Margin	-3.3%-0.6pp	-2.6%	N/A	-29.8%+13.3pp	-43.1%+59.5pp	-102.7%

Metric	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23	Q1'23
Gross Margin	63.5%-2.7pp	66.1%-3.3pp	69.4%+2.9pp	66.5%-5.8pp	72.3%-1.6pp	73.9%-4.0pp	77.9%+4.7pp	73.2%
Operating Margin	-13.0%-2.2pp	-10.8%-23.9pp	13.1%+23.6pp	-10.4%-4.8pp	-5.6%+5.8pp	-11.4%-28.2pp	16.8%+21.6pp	-4.9%
Net Margin	-69.8%-83.9pp	14.1%-7.5pp	21.6%+16.8pp	4.9%-4.0pp	8.9%+29.5pp	-20.6%-19.4pp	-1.2%+44.4pp	-45.6%
Return on Equity	N/A	8.5%-3.0pp	11.4%+8.9pp	2.6%-2.4pp	4.9%	N/A	N/A	N/A
Return on Assets	-8.7%-10.3pp	1.6%-1.7pp	3.2%+2.5pp	0.7%-0.6pp	1.3%+3.5pp	-2.2%-2.1pp	-0.2%+5.9pp	-6.1%
Current Ratio	1.16-0.1	1.23+0.2	1.03+0.0	0.99	N/A	0.85-0.3	1.11+0.0	1.08
Debt-to-Equity	0.70+0.3	0.45+0.2	0.27-0.1	0.32-0.0	0.35+0.3	0.00-0.5	0.46-0.0	0.47
FCF Margin	24.1%+28.6pp	-4.5%+30.9pp	-35.4%-53.2pp	17.9%+25.9pp	-8.0%-6.2pp	-1.8%	N/A	N/A

Similar Companies

Gelteq Limited GELS

$8.5M

Flora Growth Corp FLGC

$21.6M

Therapeuticsmd Inc TXMD

$27.3M

Frequently Asked Questions

What is Aytu Biopharma Inc's annual revenue?

Aytu Biopharma Inc (AYTU) reported $66.4M in total revenue for fiscal year 2025. This represents a 1.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Aytu Biopharma Inc's revenue growing?

Aytu Biopharma Inc (AYTU) revenue grew by 1.8% year-over-year, from $65.2M to $66.4M in fiscal year 2025.

Is Aytu Biopharma Inc profitable?

No, Aytu Biopharma Inc (AYTU) reported a net income of -$13.6M in fiscal year 2025, with a net profit margin of -20.4%.

What is Aytu Biopharma Inc's EBITDA?

Aytu Biopharma Inc (AYTU) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Aytu Biopharma Inc have?

As of fiscal year 2025, Aytu Biopharma Inc (AYTU) had $31.0M in cash and equivalents against $10.9M in long-term debt.

What is Aytu Biopharma Inc's gross margin?

Aytu Biopharma Inc (AYTU) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Aytu Biopharma Inc's operating margin?

Aytu Biopharma Inc (AYTU) had an operating margin of -11.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Aytu Biopharma Inc's net profit margin?

Aytu Biopharma Inc (AYTU) had a net profit margin of -20.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Aytu Biopharma Inc's free cash flow?

Aytu Biopharma Inc (AYTU) generated -$2.2M in free cash flow during fiscal year 2025. This represents a -26.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Aytu Biopharma Inc's operating cash flow?

Aytu Biopharma Inc (AYTU) generated -$1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aytu Biopharma Inc's total assets?

Aytu Biopharma Inc (AYTU) had $124.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Aytu Biopharma Inc's capital expenditures?

Aytu Biopharma Inc (AYTU) invested $228K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Aytu Biopharma Inc spend on research and development?

Aytu Biopharma Inc (AYTU) invested $1.3M in research and development during fiscal year 2025.

How many shares does Aytu Biopharma Inc have outstanding?

Aytu Biopharma Inc (AYTU) had 9M shares outstanding as of fiscal year 2025.

What is Aytu Biopharma Inc's current ratio?

Aytu Biopharma Inc (AYTU) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.

What is Aytu Biopharma Inc's debt-to-equity ratio?

Aytu Biopharma Inc (AYTU) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aytu Biopharma Inc's return on assets (ROA)?

Aytu Biopharma Inc (AYTU) had a return on assets of -10.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aytu Biopharma Inc's cash runway?

Based on fiscal year 2025 data, Aytu Biopharma Inc (AYTU) had $31.0M in cash against an annual operating cash burn of $1.9M. This gives an estimated cash runway of approximately 192 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aytu Biopharma Inc's Piotroski F-Score?

Aytu Biopharma Inc (AYTU) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aytu Biopharma Inc's earnings high quality?

Aytu Biopharma Inc (AYTU) has an earnings quality ratio of 0.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Aytu Biopharma Inc cover its interest payments?

Aytu Biopharma Inc (AYTU) has an interest coverage ratio of -2.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Aytu Biopharma Inc?

Aytu Biopharma Inc (AYTU) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.